Literature DB >> 30473183

Review of the economic evidence presented to the United States Advisory Committee on Immunization Practices, 2012-2016.

Jamison Pike1, Andrew J Leidner2, Jessica R MacNeil3, Amanda C Cohn3.   

Abstract

We identified 16 Advisory Committee on Immunization Practices (ACIP) presentations from 2012 to 2016 that indicated 'cost' or 'economic' content. Characteristics were reviewed, abstracted, and tabulated to quantify and assess the transparency and consistency of economic evidence presented to ACIP. To assess transparency, we documented if each study identified author affiliation, conflicts of interest, study limitations, a clearly described model structure and other model attributes. To assess consistency, we identified the frequency of specific modeling choices, including the perspective, types of health outcomes considered, inclusion of specific types of costs, discount rate, and use of sensitivity analyses. Our results indicate that the content in these presentations appear to be transparent overall and consistent in several important areas, such as study perspective and health outcomes. However, we find the inclusion of particular types of direct costs, indirect costs, program costs, and sensitivity analyses are areas that could improve consistency. Published by Elsevier Ltd.

Entities:  

Keywords:  Advisory Committee on Immunization Practices; Cost-effectiveness; Economics; Immunization

Mesh:

Substances:

Year:  2018        PMID: 30473183      PMCID: PMC6451648          DOI: 10.1016/j.vaccine.2018.11.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Eliminating waste in US health care.

Authors:  Donald M Berwick; Andrew D Hackbarth
Journal:  JAMA       Date:  2012-03-14       Impact factor: 56.272

2.  Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.

Authors:  Charles Stoecker; Lindsay Kim; Ryan Gierke; Tamara Pilishvili
Journal:  J Gen Intern Med       Date:  2016-03-14       Impact factor: 5.128

Review 3.  Resurgence of Vaccine-Preventable Diseases in the United States: Anesthetic and Critical Care Implications.

Authors:  Grete H Porteous; Neil A Hanson; Lila Ann A Sueda; Carli D Hoaglan; Aaron B Dahl; Brooks B Ohlson; Brian E Schmidt; Chia C Wang; R Eliot Fagley
Journal:  Anesth Analg       Date:  2016-05       Impact factor: 5.108

4.  Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.

Authors:  Marc Brisson; Jean-François Laprise; Harrell W Chesson; Mélanie Drolet; Talía Malagón; Marie-Claude Boily; Lauri E Markowitz
Journal:  J Natl Cancer Inst       Date:  2015-10-04       Impact factor: 13.506

5.  Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis.

Authors:  Jean-François Laprise; Lauri E Markowitz; Harrell W Chesson; Mélanie Drolet; Marc Brisson
Journal:  J Infect Dis       Date:  2016-05-27       Impact factor: 5.226

6.  The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.

Authors:  Harrell W Chesson; Lauri E Markowitz; Susan Hariri; Donatus U Ekwueme; Mona Saraiya
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

7.  Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States.

Authors:  Hajime Kamiya; Bo-Hyun Cho; Mark L Messonnier; Thomas A Clark; Jennifer L Liang
Journal:  Vaccine       Date:  2016-02-17       Impact factor: 3.641

8.  Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.

Authors:  Ayman Chit; Debbie L Becker; Carlos A DiazGranados; Michael Maschio; Eddy Yau; Michael Drummond
Journal:  Lancet Infect Dis       Date:  2015-09-08       Impact factor: 25.071

9.  Economic evaluation of the routine childhood immunization program in the United States, 2009.

Authors:  Fangjun Zhou; Abigail Shefer; Jay Wenger; Mark Messonnier; Li Yan Wang; Adriana Lopez; Matthew Moore; Trudy V Murphy; Margaret Cortese; Lance Rodewald
Journal:  Pediatrics       Date:  2014-03-03       Impact factor: 7.124

10.  Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.

Authors:  Bo-Hyun Cho; Charles Stoecker; Ruth Link-Gelles; Matthew R Moore
Journal:  Vaccine       Date:  2013-10-19       Impact factor: 3.641

View more
  3 in total

Review 1.  A review of the cost-effectiveness of adult influenza vaccination and other preventive services.

Authors:  Nazila M Dabestani; Andrew J Leidner; Eric E Seiber; Hyoshin Kim; Samuel B Graitcer; Ivo M Foppa; Carolyn B Bridges
Journal:  Prev Med       Date:  2019-05-29       Impact factor: 4.018

2.  Insurance reimbursements for recombinant zoster vaccine in the private sector.

Authors:  Andrew J Leidner; Zhaoli Tang; Angela Guo; Tara C Anderson; Yuping Tsai
Journal:  Vaccine       Date:  2021-08-02       Impact factor: 4.169

Review 3.  Data Needs for Economic Evaluations of Screening in Pediatric Primary Care: A Research Framework.

Authors:  Scott D Grosse; Alex R Kemper; Lisa A Prosser
Journal:  Pediatrics       Date:  2021-07       Impact factor: 9.703

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.